老年人潜在不适当处方发生率:门诊电子病历纵向研究
该回顾性队列研究基于美国宾夕法尼亚州西部多站点门诊电子病历(2015-2018年),纳入342,405名患者、893,754人年随访,排除 prevalent 病例,按2019年Beers标准自动编码评估潜在不适当用药(PIM)处方发生率。结果显示至少1种PIM的发生率为193.5/1000人年,以短中效苯二氮䓬类、第一代抗组胺药和骨骼肌松弛剂为主;白人、高共病负担和PACE/PACENET药物补贴与更高风险相关,男性及年龄增长与风险降低相关。
要点
- 至少1种PIM的发生率为193.5/1000人年,短中效苯二氮䓬类(37.6)、第一代抗组胺药(32.8)和骨骼肌松弛剂(22.0)居前。
- 白人患者PIM发生率高出15%,男性低35%;Charlson评分≥3者风险高59%,PACE/PACENET参与者风险高83%。
- 年龄每增加1岁,PIM发生率降低1.2%,提示风险随年龄并非线性上升。
核心结论
- 该研究为门诊老年人PIM处方发生率建立了基准,并识别出按PIM类别而异的风险差异。
研究设计与样本
- 回顾性研究,基于2015-2018年多站点门诊电子病历,排除 prevalent 病例,纳入342,405名患者、893,754人年随访。
主要发现
- 至少1种PIM的发生率为193.5/1000人年,短中效苯二氮䓬类37.6、第一代抗组胺药32.8、骨骼肌松弛剂22.0/1000人年。
- 白人患者PIM发生率比参照高15%,男性低35%;Charlson评分≥3与风险高59%相关;PACE/PACENET参与与风险高83%相关;年龄每增1岁风险降低1.2%。
关键数值与推荐
- PIM判定基于2019年Beers标准自动编码。
- 多变量Poisson回归评估年龄、性别、种族、共病和药物补贴对PIM风险的影响;各PIM类别用比例风险模型分析预测因素与至处方时间的关系。
临床怎么用
- 老年医学科可参照193.5/1000人年的基准监测门诊PIM处方,优先关注苯二氮䓬类、第一代抗组胺药和骨骼肌松弛剂。
- 对高共病(Charlson≥3)、白人及接受PACE/PACENET药物补贴的老年患者,应加强PIM风险审核与用药优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The incidence of potentially inappropriate medication (PIM) prescribing among older adults is not as well studied as its prevalence. Estimates of factors associated with PIM incidence, such as patient age, sex, race-ethnicity, medication subsidy support, and comorbidity, are also limited. OBJECTIVE: To estimate the incidence of PIM prescribing in older adult outpatients, as well as the incidence and predictors for each PIM class, in a large outpatient electronic health records (EHR) cohort. DESIGN: Retrospective study of PIM prescribing among outpatients with encounters leading to prescription orders, 2015-2018, excluding prevalent cases. SETTING: Outpatients receiving care from a multi-site health system in western Pennsylvania. PARTICIPANTS: 342,405 patients, contributing 893,754 person-years of follow-up. MAIN OUTCOMES AND MEASURES: The incidence of PIM prescribing based on automated coding of 2019 Beers criteria. A multivariable Poisson regression model was estimated to assess the impact of age, sex, race-ethnicity, comorbidity, and medication subsidy (PACE/PACENET) on PIM risk. For each PIM class, the association between predictors and time to PIM prescribing was evaluated using proportional hazard models. RESULTS: The incidence rate (IR) for 1 or more PIM was 193.5 per 1000 person-years, led by short- and intermediate-acting benzodiazepines (37.6), first-generation antihistamines (32.8), and skeletal muscle relaxants (22.0). The incidence of PIM prescribing was 15% higher among white patients and 35% lower among males. High comorbidity (Charlson score ≥ 3) was associated with a 59% higher risk. Participation in the PACE/PACENET program, a medication subsidy program, was associated with an 83% increase in incidence. Each additional year of age was associated with a 1.2% reduction in incidence. CONCLUSIONS AND RELEVANCE: This study establishes benchmarks for the incidence of PIM prescribing in outpatients and identifies important disparities in PIM risk, which vary by PIM class.
引用
- Albert SM, Li X, Kane-Gill SL, et al. Incidence of Potentially Inappropriate Prescribing: Longitudinal Investigation of Outpatient EHR Prescriptions. J Am Geriatr Soc. 2024. PMID: 39739457. doi:10.1111/jgs.19340
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。